Last reviewed · How we verify
Ilidar (azapetine)
Ilidar (generic name: azapetine) is a azapetine drug. It is currently in unknown development for Peripheral vascular disease.
Ilidar works by inhibiting platelet aggregation, which helps to improve blood flow and reduce the risk of blood clots.
Ilidar (azapetine) is a small molecule drug in the azapetine class, used to treat peripheral vascular disease. Its exact mechanism of action is unknown, but it is believed to work by inhibiting platelet aggregation and improving blood flow. Ilidar's commercial status is unclear, and it may be patented or off-patent. As a pharmaceutical professional, it is essential to consider the potential risks and benefits of this medication, including any key safety considerations. Further research is needed to fully understand Ilidar's efficacy and safety profile.
At a glance
| Generic name | azapetine |
|---|---|
| Drug class | azapetine |
| Therapeutic area | Hematology |
| Phase | unknown |
Mechanism of action
Think of platelets like tiny messengers in your blood that help your body form clots when you're injured. When platelets get too active, it can lead to problems like blood clots and poor circulation. Ilidar helps to calm down these platelets, making it easier for blood to flow and reducing the risk of complications.
Approved indications
- Peripheral vascular disease
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ilidar CI brief — competitive landscape report
- Ilidar updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Ilidar
What is Ilidar?
How does Ilidar work?
What is Ilidar used for?
What is the generic name of Ilidar?
What drug class is Ilidar in?
What development phase is Ilidar in?
Related
- Drug class: All azapetine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Peripheral vascular disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing